JP2013535963A5 - - Google Patents

Download PDF

Info

Publication number
JP2013535963A5
JP2013535963A5 JP2013519215A JP2013519215A JP2013535963A5 JP 2013535963 A5 JP2013535963 A5 JP 2013535963A5 JP 2013519215 A JP2013519215 A JP 2013519215A JP 2013519215 A JP2013519215 A JP 2013519215A JP 2013535963 A5 JP2013535963 A5 JP 2013535963A5
Authority
JP
Japan
Prior art keywords
seq
diabetes
isolated
complex
high affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013519215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535963A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2011/000563 external-priority patent/WO2012007950A2/en
Publication of JP2013535963A publication Critical patent/JP2013535963A/ja
Publication of JP2013535963A5 publication Critical patent/JP2013535963A5/ja
Pending legal-status Critical Current

Links

JP2013519215A 2010-07-15 2011-07-14 Mhcクラスiiと糖尿病関連自己抗原性ペプチドとの天然型複合体に対するt細胞受容体様特異性を有する単離された高親和性実体 Pending JP2013535963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36443710P 2010-07-15 2010-07-15
US61/364,437 2010-07-15
PCT/IL2011/000563 WO2012007950A2 (en) 2010-07-15 2011-07-14 Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides

Publications (2)

Publication Number Publication Date
JP2013535963A JP2013535963A (ja) 2013-09-19
JP2013535963A5 true JP2013535963A5 (cg-RX-API-DMAC7.html) 2014-08-28

Family

ID=44504047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013519215A Pending JP2013535963A (ja) 2010-07-15 2011-07-14 Mhcクラスiiと糖尿病関連自己抗原性ペプチドとの天然型複合体に対するt細胞受容体様特異性を有する単離された高親和性実体

Country Status (5)

Country Link
US (1) US20130189284A1 (cg-RX-API-DMAC7.html)
EP (1) EP2593480A2 (cg-RX-API-DMAC7.html)
JP (1) JP2013535963A (cg-RX-API-DMAC7.html)
CA (1) CA2805478A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012007950A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2805479A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
MX386164B (es) * 2014-09-26 2025-03-18 Univ British Columbia Una combinación de quinurenina y células presentadoras de antígeno (apc) como productos terapéuticos y métodos para uso en modulación inmunitaria.
US10473647B1 (en) 2014-11-21 2019-11-12 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
GB201506112D0 (en) * 2015-04-10 2015-05-27 Midatech Ltd And Inst Nationale De La Sant� Et De Al Rech Medicale And University College Car Nanoparticle-based antigen specific immunotherapy
US20190031759A1 (en) 2015-04-30 2019-01-31 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
US11179448B2 (en) 2015-07-16 2021-11-23 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory T cells and use of same in immunotherapy
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520603D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
EP3571295B1 (en) 2017-01-18 2026-01-07 Yeda Research and Development Co. Ltd Genetically modified veto cells and use of same in immunotherapy
US12153056B2 (en) 2019-07-15 2024-11-26 Washington University Compositions for and methods of diagnosing, prognosing, and treating diabetes
EP4384603A1 (en) 2021-08-10 2024-06-19 Gamida-Cell Ltd. Engineered nk cells, methods of their production and uses thereof
GB202210967D0 (en) * 2022-07-27 2022-09-07 Univ Birmingham Tolerogenic peptides i
EP4561603A1 (en) * 2022-07-29 2025-06-04 Repertoire Immune Medicines, Inc. T cell epitopes associated with type 1 diabetes

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
DE19525784A1 (de) 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
KR19990063648A (ko) * 1995-09-21 1999-07-26 프레드한 아룬디프 에스 글루타민산 데카복실라제에 대한 항체와 폴리(에틸렌 글리콜)공액물을 섬세포에 제공하는 방법
US6037137A (en) 1997-02-20 2000-03-14 Oncoimmunin, Inc. Fluorogenic peptides for the detection of protease activity
AU741130B2 (en) * 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US20030166277A1 (en) 2000-04-12 2003-09-04 University Of Rochester Targeted vaccine delivery systems
AU2001293735B2 (en) * 2000-08-14 2006-05-25 N.V. Organon Use of antibodies against specific MHC-peptide complexes
EP1578775A4 (en) * 2002-07-12 2009-02-11 Dana Farber Cancer Inst Inc NEW COMPOSITIONS AND METHOD FOR GENERATING MHC CLASS II COMPOUNDS BY PEPTIDE EXCHANGE
CA2574665C (en) * 2004-07-23 2014-07-15 The Walter And Eliza Hall Institute Of Medical Research Therapeutic and diagnostic agents
CA2638892A1 (en) * 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells
EP3269384A1 (en) 2007-03-07 2018-01-17 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions

Similar Documents

Publication Publication Date Title
JP2013535963A5 (cg-RX-API-DMAC7.html)
JP2013538555A5 (cg-RX-API-DMAC7.html)
CA2861793C (en) Method of providing monoclonal auto-antibodies with desired specificity
JP2012143232A5 (cg-RX-API-DMAC7.html)
JP2018527884A5 (cg-RX-API-DMAC7.html)
RU2013107776A (ru) Антитело к противоопухолевому антигену и способы применения
RU2015141418A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
JP2021107397A (ja) 抗il23抗体を使用してクローン病を治療するための方法
JP2015506945A5 (cg-RX-API-DMAC7.html)
CA2792740A1 (en) Antibodies with ph dependent antigen binding
JP2019515646A (ja) Pd−l1に対する結合メンバー
JP2010511388A5 (cg-RX-API-DMAC7.html)
US10131709B2 (en) Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
JP2012518425A5 (cg-RX-API-DMAC7.html)
JP2012531212A5 (cg-RX-API-DMAC7.html)
JP2014526898A5 (cg-RX-API-DMAC7.html)
JP2018502060A5 (cg-RX-API-DMAC7.html)
RU2017134140A (ru) Конструкции, направленные на комплексы пептида аfp/мнс, и виды их использования
HRP20220553T1 (hr) Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
JP2012501670A5 (cg-RX-API-DMAC7.html)
JP2016503412A5 (ja) Il−6アンタゴニストおよびその使用
JP2009533021A5 (cg-RX-API-DMAC7.html)
RU2016124163A (ru) Сконструированные высокоаффинные t-клеточные рецепторы человека
CN110054690A (zh) 用于治疗的抗adm抗体或抗adm抗体片段
RU2014134043A (ru) Анти-cxcr3 антитела